| Primary |
| Fungal Infection |
14.7% |
| Candidiasis |
8.0% |
| Atrial Fibrillation |
7.0% |
| Urinary Tract Infection |
7.0% |
| Lung Disorder |
5.6% |
| Oesophageal Candidiasis |
5.6% |
| Pain |
5.2% |
| Sepsis |
5.2% |
| Infection |
4.9% |
| Oral Candidiasis |
4.9% |
| Thrombosis Prophylaxis |
4.2% |
| Hiv Infection |
3.8% |
| Nausea |
3.5% |
| Prophylaxis |
3.5% |
| Non-hodgkin's Lymphoma |
3.1% |
| Oral Fungal Infection |
3.1% |
| Drug Use For Unknown Indication |
2.8% |
| Product Used For Unknown Indication |
2.8% |
| Candida Infection |
2.4% |
| Depression |
2.4% |
|
| International Normalised Ratio Increased |
11.8% |
| Thrombocytopenia |
10.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
8.2% |
| Type 2 Diabetes Mellitus |
7.3% |
| Pancytopenia |
6.4% |
| Transaminases Increased |
6.4% |
| Vomiting |
6.4% |
| Toxic Skin Eruption |
4.5% |
| Pancreatitis Acute |
3.6% |
| Rash Maculo-papular |
3.6% |
| Renal Failure Acute |
3.6% |
| Skin Exfoliation |
3.6% |
| Stevens-johnson Syndrome |
3.6% |
| Torsade De Pointes |
3.6% |
| Vascular Purpura |
3.6% |
| Bone Marrow Failure |
2.7% |
| Clostridium Difficile Colitis |
2.7% |
| Cytolytic Hepatitis |
2.7% |
| Drug Eruption |
2.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
28.1% |
| Product Used For Unknown Indication |
16.6% |
| Lung Disorder |
6.7% |
| Infection |
6.4% |
| Unevaluable Event |
6.1% |
| Hiv Infection |
5.6% |
| Candidiasis |
3.1% |
| Pain |
2.7% |
| Prophylaxis |
2.6% |
| Urinary Tract Infection |
2.6% |
| Nausea |
2.4% |
| Febrile Bone Marrow Aplasia |
2.2% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Ascites |
2.0% |
| Leukocytosis |
2.0% |
| Pneumoperitoneum |
2.0% |
| Septic Shock |
2.0% |
| Depression |
1.9% |
| Breast Cancer |
1.6% |
| Perforated Ulcer |
1.6% |
|
| Thrombocytopenia |
29.9% |
| Toxic Skin Eruption |
12.3% |
| Toxic Epidermal Necrolysis |
4.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.9% |
| Neutropenia |
3.9% |
| Renal Failure |
3.9% |
| Stevens-johnson Syndrome |
3.9% |
| Transaminases Increased |
3.9% |
| Jaundice Cholestatic |
3.4% |
| Status Epilepticus |
3.4% |
| Cholestasis |
2.9% |
| Hepatitis Fulminant |
2.9% |
| Hepatocellular Injury |
2.9% |
| Rash |
2.9% |
| Agranulocytosis |
2.5% |
| Overdose |
2.5% |
| Pancytopenia |
2.5% |
| Renal Failure Acute |
2.5% |
| Septic Shock |
2.5% |
| Skin Exfoliation |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.1% |
| Product Used For Unknown Indication |
25.0% |
| Hiv Infection |
13.3% |
| Prophylaxis |
6.3% |
| Acute Myeloid Leukaemia |
2.1% |
| Pain |
2.1% |
| Mycobacterium Avium Complex Infection |
2.0% |
| Hypertension |
1.9% |
| Diarrhoea |
1.7% |
| Candidiasis |
1.5% |
| Antifungal Prophylaxis |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Angina Pectoris |
1.3% |
| Diabetes Mellitus |
1.2% |
| B-cell Lymphoma |
1.2% |
| Constipation |
1.2% |
| Oral Candidiasis |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
| Fungal Infection |
1.1% |
| Mitochondrial Toxicity |
1.1% |
|
| Thrombocytopenia |
11.8% |
| Weight Decreased |
7.4% |
| Toxic Skin Eruption |
5.9% |
| Vomiting |
5.9% |
| Febrile Bone Marrow Aplasia |
5.4% |
| General Physical Health Deterioration |
5.4% |
| Subdural Haematoma |
5.4% |
| Toxic Epidermal Necrolysis |
5.4% |
| Cytolytic Hepatitis |
4.9% |
| Pyrexia |
4.9% |
| Renal Failure Acute |
4.9% |
| Respiratory Failure |
4.4% |
| Septic Shock |
4.4% |
| Pancreatitis Acute |
3.9% |
| Renal Failure |
3.9% |
| Neutropenia |
3.4% |
| Sepsis |
3.4% |
| Urticaria |
3.4% |
| Bartholin's Abscess |
2.9% |
| Febrile Neutropenia |
2.9% |
|
| Interacting |
| Thrombosis Prophylaxis |
9.9% |
| Atrial Fibrillation |
8.5% |
| Drug Use For Unknown Indication |
8.5% |
| Pain |
8.5% |
| Acute Lymphocytic Leukaemia |
7.0% |
| Hypercholesterolaemia |
7.0% |
| Prophylaxis |
7.0% |
| Fungal Infection |
5.6% |
| Erysipelas |
4.2% |
| Mycosis Fungoides |
4.2% |
| Renal Cancer |
4.2% |
| Bronchitis |
2.8% |
| Coagulopathy |
2.8% |
| Cryptococcal Cutaneous Infection |
2.8% |
| Deep Vein Thrombosis |
2.8% |
| Diabetes Mellitus |
2.8% |
| Diarrhoea |
2.8% |
| Gastroenteritis Salmonella |
2.8% |
| Graft Versus Host Disease |
2.8% |
| Helicobacter Infection |
2.8% |
|
| International Normalised Ratio Increased |
20.7% |
| Drug Interaction |
6.9% |
| Hyperkalaemia |
6.9% |
| Torsade De Pointes |
6.9% |
| Vomiting |
6.9% |
| Cough |
3.4% |
| Drug Level Increased |
3.4% |
| Haemoptysis |
3.4% |
| Leukoencephalopathy |
3.4% |
| Malaise |
3.4% |
| Myoclonic Epilepsy |
3.4% |
| Overdose |
3.4% |
| Rectal Adenoma |
3.4% |
| Renal Haemorrhage |
3.4% |
| Rhabdomyolysis |
3.4% |
| Somnolence |
3.4% |
| Subdural Haematoma |
3.4% |
| Tachycardia |
3.4% |
| Thrombocytopenia |
3.4% |
| Vaginal Haemorrhage |
3.4% |
|
